Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects

AIM: Anacetrapib is currently being developed for the treatment of dyslipidaemia. Since warfarin, an anticoagulant with a narrow therapeutic index, is expected to be commonly prescribed in this population, a drug interaction study was conducted. METHODS: In a randomized, open-label, two-period fixed...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Krishna, Rajesh, Stypinski, Daria, Ali, Melissa, Garg, Amit, Cote, Josee, Maes, Andrea, DeGroot, Bruce, Liu, Yang, Li, Susie, Connolly, Sandra M, Wagner, John A, Stoch, S Aubrey
Formato: Artigo
Lenguaje:Inglês
Publicado: Blackwell Science Inc 2012
Materias:
Drug Interactions
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3394135/
https://ncbi.nlm.nih.gov/pubmed/22243494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2012.04171.x
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares